s6y

Chemomab Therapeutics Ltd.

Ticker
CMMB
CIK
1534248
Industry
Pharmaceutical Preparations
Formerly
Anchiano Therapeutics Ltd., BioCancell Ltd.

Financials 14

  1. 10-Q Quarterly Report for period ending Mar 31, 2023
  2. 10-K Annual Report for period ending Dec 31, 2022
  3. 10-Q Quarterly Report for period ending Sep 30, 2022
  4. 10-Q Quarterly Report for period ending Jun 30, 2022
  5. 10-Q Quarterly Report for period ending Mar 31, 2022
  6. 10-K Annual Report for period ending Dec 31, 2021
  7. 10-Q Quarterly Report for period ending Sep 30, 2021
  8. 10-Q Quarterly Report for period ending Jun 30, 2021
  9. 10-Q Quarterly Report for period ending Mar 31, 2021
  10. 10-K Annual Report for period ending Dec 31, 2020

All 14 financials filings

News 50

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K/A Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 50 news filings

Ownership 112

  1. 4 Statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 3 Initial statement of beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 112 ownership filings

Prospectus 41

  1. S-4/A Registration of securities issued in business combination transactions
  2. S-4/A Registration of securities issued in business combination transactions
  3. S-4 Registration of securities issued in business combination transactions
  4. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. RW Registration Withdrawal Request
  9. S-1/A General form of registration statement for all companies including face-amount certificate companies
  10. S-1/A General form of registration statement for all companies including face-amount certificate companies

All 41 prospectus filings

Proxies 14

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFM14A Definitive proxy statement relating to a merger, acquisition, or disposition
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 14 proxies filings

Other 138

  1. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  2. SCHEDULE 13D
  3. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  4. EFFECT Notice of Effectiveness
  5. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  6. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  7. SCHEDULE 13D/A
  8. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  9. SCHEDULE 13G
  10. SCHEDULE 13G/A

All 138 other filings